Balciuniene J, Emilsson L, Oreland L, et al. 2002. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet, 110:1–7. Barden N, Reul JM, Holsboer F. 1995. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci, 18:6–11. Battersby S, Ogilvie AD, Blackwood DHR, et al. 1999. Presence of multiple functional polyadenylation signals and a single nucleotide polymorphism in the 3´ untranslated region of the human serotonin transporter gene. J Neurochem, 72:1384–8. Bauman AL, Apparsundaram S, Ramamoorthy S, et al. 2000. Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J Neurosci, 20:7571–8. Bayer KU, Schulman H. 2001. Regulation of signal transduction by protein targeting: the case for CaMKII. Biochem Biophys Res Commun, 289:917–23. Bjelland I, Tell GS, Vollset SE, et al. 2003. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry, 60:618–26. Blier P, de Montigny C. 1994. Current advances and trends in the treatment of depression. Trends Pharmacol Sci, 15:220–5. Blier P, Ward NM. 2003. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry, 53:193–203. Bondy B, Baghai TC, Zill P, et al. 2002. Combined action of the ACE D- and the G-protein beta3 T-allele in major depression: a possible link to cardiovascular disease? Mol Psychiatry, 7:1120–6. Bondy B, Kuznik J, Baghai T, et al. 2000. Lack of association of serotonin- 2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet, 96:831–5. Bonhomme N, Esposito E. 1998. Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J Clin Psychopharmacol, 18:447–54. Botstein D, Risch N. 2003. Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex disease. Nat Genet, 33:228–36. Bourin M, David DJ, Jolliet P, et al. 2002. Mechanism of action of antidepressants and therapeutic perspectives. Therapie, 57:385–96. Brady LS, Whitfield HJJ, Fox RJ, et al. 1991. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain: therapeutic implications. J Clin Invest, 87:831–7. Bristow LJ, O’Connor D, Watts R, et al. 2000. Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat. Neuropharmacology, 39:1222–36. Brosen K. 1993. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig, 71:1002–9. Buck KJ. 1995. Strategies for mapping and identifying quantitative trait loci specifying behavioral responses to alcohol. Alcohol Clin Exp Res, 19:795–801. Buysse DJ. 2004. Insomnia, depression and aging. Assessing sleep and mood interactions in older adults. Geriatrics, 59:47–51. Caberlotto L, Fuxe K, Overstreet DH, et al. 1998. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Brain Res Mol Brain Res, 59:58–65. Cai X, Gu Z, Zhong P, et al. 2002. Serotonin 5-HT1A receptors regulate AMPA receptor channels through inhibiting Ca2+/calmodulin- dependent kinase II in prefrontal cortical pyramidal neurons. J Biol Chem, 277:36553–62. Caspi A, Sugden K, Moffitt TE, et al. 2003. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 301:368–89. Catalano M. 1999. The challenges of psychopharmacogenetics. Am J Hum Genet, 65:606–10. Neuropsychiatric Disease and Treatment 2005:1(1) Candidate genes for SSRI response Catalano M. 2001. Functionally gene-linked polymorphic regions and genetically controlled neurotransmitters metabolism. Eur Neuropsychopharmacol, 11:431–9. Celano E, Tiraboschi E, Consogno E, et al. 2003. Selective regulation of presynaptic calcium/calmodulin-dependent protein kinase II by psychotropic drugs. Biol Psychiatry, 53:442–9. Chang A, Li PP, Warsh JJ. 2003. cAMP-Dependent protein kinase (PKA) subunit mRNA levels in postmortem brain from patients with bipolar affective disorder (BD). Brain Res Mol Brain Res, 116:27–37. Chang BH, Mukherji S, Soderling TR. 2001. Calcium/calmodulin- dependent protein kinase II inhibitor protein: localization of isoforms in rat brain. Neuroscience, 102:767–77. Chau D, Rada PV, Kosloff RA, et al. 1999. Cholinergic, M1 receptors in the nucleus accumbens mediate behavioral depression. A possible downstream target for fluoxetine. Ann N Y Acad Sci, 877:769–74. Chen AC, LaForge KS, Ho A, et al. 2002. Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet, 114:429–35. Cherry JA, Davis RL. 1999. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol, 407:287–301. Chiavegatto S, Nelson RJ. 2003. Interaction of nitric oxide and serotonin in aggressive behavior. Horm Behav, 44:223–41. Chidiac P, Roy AA. 2003. Activity, regulation, and intracellular localization of RGS proteins. Receptors Channels, 9:135–47. Claes S, Villafuerte S, Forsgren T, et al. 2003. The corticotropin-releasing hormone binding protein is associated with major depression in a population from Northern Sweden. Biol Psychiatry, 54:867–72. Cohen LJ, De Vane CL. 1996. Clinical implications of antidepressant pharmacokinetics and pharmacogenetics. Ann Pharmacother, 30:1471–80. Cohen PTW. 1997. Novel protein serine/threonine phosphatases: variety is the spice of life. Trends Biochem Sci, 22:245–51. Comings DE, Wu S, Rostamkhani M, et al. 2002. Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women. Am J Med Genet, 114:527–9. Consogno E, Racagni G, Popoli M. 2001. Modifications in brain CaM kinase II after long-term treatment with desmethylimipramine. Neuropsychopharmacology, 24:21–30. Conti AC, Cryan JF, Dalvi A, et al. 2002. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci, 22:3262–8. Cowan WM, Kopnisky KL, Hyman SE. 2002. The human genome project and its impact on psychiatry. Annu Rev Neurosci, 25:1–50. Cusin C, Serretti A, Zanardi R, et al. 2002. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol, 5:27–35. da Cruz e Silva EF, Fox CA, Ouiment CC, et al. 1995. Differential expression of protein phosphatase 1 isoforms in mammalian brain. J Neurosci, 15:3375–89. Daly AK. 2003. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol, 17:27–41. Day M, Olson PA, Platzer J, et al. 2002. Stimulation of 5-HT(2) receptors in prefrontal pyramidal neurons inhibits Ca(v)1.2 L type Ca(2+) currents via a PLCbeta/IP3/calcineurin signaling cascade. J Neurophysiol, 87:2490–504. Defer N, Best-Belpomme M, Hanoune J. 2000. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol, 279:F400–16. Dekeyne A, Denorme B, Monneyron S, et al. 2000. Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors. Neuropharmacology, 39:1114–17. DeRijk RH, Schaaf M, de Kloet ER. 2002. Glucocorticoid receptor variants: clinical implications. J Steroid Biochem Mol Biol, 81:103–22. 29